What development phase is Respiride in?

Respiride is FDA-approved (marketed).

What is the generic name of Respiride?

FENSPIRIDE is the generic (nonproprietary) name of Respiride.

Last reviewed 2026-04-20 · How we verify

Respiride (FENSPIRIDE)

FDA-approved withdrawn Small molecule Quality 15/100

Fenspiride (Respiride) is a marketed drug that operates by blocking potassium channels in the airway smooth muscle, resulting in bronchodilation and improved breathing. Its key strength lies in its unique mechanism of action, which differentiates it from other bronchodilators. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	FENSPIRIDE
Drug class	fenspiride
Modality	Small molecule
Therapeutic area	Respiratory
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Respiride CI brief — competitive landscape report
Respiride updates RSS · CI watch RSS